Guardant Shares Rise After FDA Approves Colon Cancer Blood Test.

COLON cancer; STOCK prices; COLORECTAL cancer; SCREEN time; MEDICAL screening

The US Food and Drug Administration has approved Guardant Health Inc.'s blood test, known as Shield, as a primary screening tool for colorectal cancer in adults aged 45 and older who are at average risk for the disease. This is the first blood test to be approved as a first-line screening option for colorectal cancer, which is the second-leading cause of cancer-related death in the US. Colorectal cancer rates have been increasing in younger Americans, prompting the US Preventive Services Task Force to lower the recommended age for colorectal cancer screening from 50 to 45. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)